ArticleJournal of oncology2022
Epithelioid Hemangioendothelioma: Incidence, Mortality, Prognostic Factors, and Survival Analysis Using the Surveillance, Epidemiology, and End Results Database.
Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Characteristics of patients with epithelioid hemangioendothelioma (EHE): a retrospective analysis of the Charité- Universitätsmedizin Berlin.Journal of cancer research and clinical oncology · 2026Article
- An epithelioid hemangioendothelioma with a novel RREB1::TFE3 gene fusion.Virchows Archiv : an international journal of pathology · 2026Article
- Primary Vaginal Epithelioid Haemangioendothelioma with Pulmonary Metastasis:Sultan Qaboos University medical journal · 2026Review
- A Rare Finding of Pulmonary Epithelioid Hemangioendothelioma.Case reports in pathology · 2026Article
- A rare case report of epithelioid hemangioendothelioma involving both lungs and right atrium with multi-system involvement.Frontiers in medicine · 2026Article
- Successful management of recurrent multiple intracerebral TFE3-rearranged epithelioid hemangioendothelioma with repeated intervention and active surveillance: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Primary Epithelioid Hemangioendothelioma of the Spine: A First in Africa. A Case Report and Literature Review.Clinical case reports · 2025Article
- Epithelioid hemangioendothelioma involving the superficial femoral artery and femoral vein.Journal of vascular surgery cases and innovative techniques · 2025Article
- Primary cutaneous epithelioid hemangioendothelioma of the temporal region: a case report.The Pan African medical journal · 2025Article
- Nab-Paclitaxel Based Chemotherapy in the Treatment of Advanced Epithelioid Hemangioendothelioma: A Single-Institution Experience.Cancer management and research · 2025Article
- Hepatic epithelioid hemangioendothelioma, a rare liver tumor: a case report and review of the literature.Frontiers in oncology · 2025Article
- Case Report: A case of epithelioid hemangioendothelioma of the right femoral artery misdiagnosed as arterial occlusion.Frontiers in surgery · 2025Article
- Diaphragm epithelioid hemangioendothelioma: a rare case report.BMC geriatrics · 2024Article
- Long-term prognosis and treatment modalities of hepatic epithelioid hemangioendothelioma: a retrospective study of 228 patients.BMC cancer · 2024Article
- Diffuse skin erythematous plaque as a manifestation of epithelioid hemangioendothelioma: A case report.Heliyon · 2024Article
- Short-term outcomes of combined therapy with sirolimus and interferon-alpha 2b for advanced hepatic epithelioid hemangioendothelioma.Therapeutic advances in medical oncology · 2024Article
- Rare cancer with primary pleural epithelioid hemangioendothelioma diagnosed by thoracoscopic biopsy achieving disease control after 16 months: case report and literature review.Frontiers in pharmacology · 2024Article
- Article
- Anteroposterior Combined Surgery of a Rare Massive Epithelioid Hemangioendothelioma at the Cervicothoracic Junction.Cureus · 2023Article
- Incidence, demographics, and survival of malignant hemangioendothelioma in the United States.Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although epithelioid hemangioendothelioma (EHE) is a rare and aggressive vascular tumor, its demographic characteristics remain unclear. We used the surveillance, epidemiology, and end results (SEER) database to determine the clinical features, incidence, and prognostic factors associated with overall survival in patients with EHE. Methods: The demographic and clinical data of patients with EHE were extracted from the SEER database (1975-2019) to calculate the incidence of EHE and survival rate in these patients. The Cox proportional hazards model and Kaplan-Meier method were used to analyze the prognostic factors of overall survival in these patients. A nomogram and time-dependent receiver operating characteristic (ROC) curve were employed to predict the 3- and 5-year survival rate. Results: The overall incidence rate (IR) of EHE was 0.230 (95%confidence interval [CI] = 0.201-0.263) per 1,000,000 person-years. According to the age-stratified IR, the highest age-adjusted IR was observed in patients aged 60-79 years (0.524 per 1,000,000 person-years, 95%CI = 0.406-0.665). The majority (30.8%) of the tumors were located in the soft tissue and skin, followed by lesions in the abdomen (28%), respiratory system (19%), bone and joint (8.6%), and others. The 5-year overall survival rate was 55.6% (95%CI = 32.8-73.5%). Multiple Cox regression analysis revealed that age >80 years (hazard ratio [HR] = 8.57, 95%CI = 2.32-31.63, Conclusion: EHE is a relatively rare vascular tumor, which principally occurs in the soft tissue and skin. It most commonly occurs in patients aged 60-79 years and its incidence has increased in recent years. Age at diagnosis, race, and tumor location may affect the overall survival outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.